{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:18:34Z","timestamp":1787894314476,"version":"build-2784847793"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      APDS is a combined immunodeficiency disorder, characterized by impaired antibody production and lymphoproliferation, with a high risk of malignancy and autoimmunity. The disease may be caused by autosomal dominant gain-of-function variants in the\n                      <jats:italic>PIK3CD<\/jats:italic>\n                      or loss-of-function variants in the\n                      <jats:italic>PIK3R1<\/jats:italic>\n                      gene.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case summary<\/jats:title>\n                    <jats:p>\n                      We report an 11-year-old girl with a history of recurrent respiratory infections, lymphoproliferation, and hepatosplenomegaly from early childhood. She was diagnosed with Hyper-IgM syndrome (HIGM) because of decreased IgA and IgG but increased IgM, and was treated with immunoglobulin replacement therapy, but there was no improvement in respiratory symptoms, and hepatosplenomegaly remained marked. Immunologic testing showed that, in addition to a reduced peripheral B-cell count, there was also a reduced CD4\n                      <jats:sup>+<\/jats:sup>\n                      T-cell count and an inverted CD4\/CD8 ratio, suggesting a diagnosis other than classical HIGM. The patient was diagnosed with APDS, confirmed by whole-exome sequencing, identifying the\n                      <jats:italic>PIK3CD<\/jats:italic>\n                      c.3061G&amp;gt;A p.(Glu1021Lys) variant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome<\/jats:title>\n                    <jats:p>The patient maintained on immunoglobulin replacement therapy and corticosteroid therapy, with subsequent addition of sirolimus, and showed a rapid response with improvement in chronic productive cough, enlarged lymph nodes, and hepatosplenomegaly after 2 months. After 6 months of treatment, lymphodenopathy had resolved, and the liver and spleen returned to normal size.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Early hepatosplenomegaly and lymphadenopathy are important warning signs of APDS in children with a Hyper IgM-like phenotype. This is particularly relevant in patients with CD4\n                      <jats:sup>+<\/jats:sup>\n                      T-cell lymphopenia, an inverted CD4\/CD8 ratio, and marked B-cell lymphopenia. Sirolimus improved lymphoproliferative manifestations and partially controlled chronic respiratory and gastrointestinal disease but did not eliminate the need for immunoglobulin replacement therapy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1881308","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:34:43Z","timestamp":1787891683000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Activated phosphoinositide 3-kinase \u03b4 syndrome mimicking Hyper-IgM syndrome: early hepatosplenomegaly as a key diagnostic clue"],"prefix":"10.3389","volume":"17","author":[{"given":"Anh T. V.","family":"Nguyen","sequence":"first","affiliation":[{"name":"Vietnam National Children\u2019s Hospital, Vietnam National Hospital of Pediatrics","place":["Hanoi, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giang D.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Vietnam National Children\u2019s Hospital, Vietnam National Hospital of Pediatrics","place":["Hanoi, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quynh T. T.","family":"Bui","sequence":"additional","affiliation":[{"name":"Vietnam National Children\u2019s Hospital, Vietnam National Hospital of Pediatrics","place":["Hanoi, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai T. P.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Vietnam National Children\u2019s Hospital, Vietnam National Hospital of Pediatrics","place":["Hanoi, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anh P.","family":"Ha","sequence":"additional","affiliation":[{"name":"Vietnam National Children\u2019s Hospital, Vietnam National Hospital of Pediatrics","place":["Hanoi, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanh H.","family":"Chu","sequence":"additional","affiliation":[{"name":"Vietnam National Children\u2019s Hospital, Vietnam National Hospital of Pediatrics","place":["Hanoi, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha T.","family":"Dang","sequence":"additional","affiliation":[{"name":"Vietnam National Children\u2019s Hospital, Vietnam National Hospital of Pediatrics","place":["Hanoi, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuc P.","family":"Ho\u00e0ng","sequence":"additional","affiliation":[{"name":"Vietnam National Children\u2019s Hospital, Vietnam National Hospital of Pediatrics","place":["Hanoi, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van D.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Children's Hospital 2","place":["Ho Chi Minh City, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tung V.","family":"Cao","sequence":"additional","affiliation":[{"name":"Vietnam National Children\u2019s Hospital, Vietnam National Hospital of Pediatrics","place":["Hanoi, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dien M.","family":"Tran","sequence":"additional","affiliation":[{"name":"Vietnam National Children\u2019s Hospital, Vietnam National Hospital of Pediatrics","place":["Hanoi, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.70962\/jhi.20250002","article-title":"The 2024 update of IUIS phenotypic classification of human inborn errors of immunity","volume":"1","author":"Bousfiha","year":"2025","journal-title":"J Hum Immun"},{"key":"B2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/ni.2771","article-title":"Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110\u03b4 result in T cell senescence and human immunodeficiency","volume":"15","author":"Lucas","year":"2014","journal-title":"Nat Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jaci.2016.06.021","article-title":"Clinical spectrum and features of activated phosphoinositide 3-kinase \u03b4 syndrome: a large patient cohort study","volume":"139","author":"Coulter","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.652405","article-title":"Activated PI3Kinase delta syndrome\u2014a multifaceted disease","volume":"9","author":"Thouenon","year":"2021","journal-title":"Front Pediatr"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2021.04.010","article-title":"Infections in activated PI3K delta syndrome (APDS)","volume":"72","author":"Brodsky","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00543","article-title":"Disease evolution and response to rapamycin in activated phosphoinositide 3-kinase \u03b4 syndrome: the European Society for Immunodeficiencies-Activated Phosphoinositide 3-kinase \u03b4 syndrome registry","volume":"9","author":"Maccari","year":"2018","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018546","article-title":"A randomized, placebo-controlled phase 3 trial of the PI3K\u03b4 inhibitor leniolisib for activated PI3K\u03b4 syndrome","volume":"141","author":"Rao","year":"2023","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10238-023-01259-y","article-title":"Systematic review of mortality and survival rates for APDS","volume":"24","author":"Hanson","year":"2024","journal-title":"Clin Exp Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.04.032","article-title":"Hematopoietic stem cell transplantation for progressive combined immunodeficiency and lymphoproliferation in patients with activated phosphatidylinositol-3-OH kinase \u03b4 syndrome type 1","volume":"143","author":"Okano","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02172","article-title":"Class-switch recombination (CSR)\/hyper-IgM (HIGM) syndromes and phosphoinositide 3-kinase (PI3K) defects","volume":"9","author":"Jhamnani","year":"2018","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4291","article-title":"Tracking CD40 signaling during germinal center development","volume":"104","author":"Basso","year":"2004","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nri3466","article-title":"Primary antibody deficiencies","volume":"13","author":"Durandy","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1735023","article-title":"Activated PI3K\u03b4 syndrome in inborn errors of immunity: diagnostic strategies and clinical challenges","volume":"16","author":"Bozkurt","year":"2026","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltae009","article-title":"Hyperactivation of the PI3K pathway in inborn errors of immunity: current understanding and therapeutic perspectives","volume":"4","author":"IJspeert","year":"2024","journal-title":"Immunother Adv"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1126\/science.1243292","article-title":"Phosphoinositide 3-kinase \u03b4 gene mutation predisposes to respiratory infection and airway damage","volume":"342","author":"Angulo","year":"2013","journal-title":"Science"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1208567","article-title":"Activated PI3K\u03b4 syndrome \u2013 reviewing challenges in diagnosis and treatment","volume":"14","author":"Vanselow","year":"2023","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2018.00402","article-title":"Evaluation of lymphoproliferative disease and increased risk of lymphoma in activated phosphoinositide 3 kinase delta syndrome: a case report with discussion","volume":"6","author":"Pham","year":"2018","journal-title":"Front Pediatr"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/cei\/uxae107","article-title":"Comparative efficacy of leniolisib (CDZ173) versus standard of care on rates of respiratory tract infection and serum immunoglobulin M (IgM) levels among individuals with activated phosphoinositide 3-kinase delta (PI3K\u03b4) syndrome (APDS): an externally controlled study","volume":"219","author":"Whalen","year":"2025","journal-title":"Clin Exp Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1881308\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:35:10Z","timestamp":1787891710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1881308\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":18,"alternative-id":["10.3389\/fimmu.2026.1881308"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1881308","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"article-number":"1881308"}}